source
- OrbiMed raises two new life sciences funds worth $3B with one aiming for AsiaThe sixth cycle of OrbiMed’s Asia Partners fund included one with more than $1 billion earmarked for life science companies based on the Eastern continent.BioSpace · 3d ago↗ source
- Estuary debuts with $103M to develop kidney disease gene therapiesEstuary Biotherapeutics raised the curtain on Friday with $103 million to support the advancement of two preclinical gene therapy candidates for the most common type of inherited kidney disease. Th…Endpoints · 3d ago↗ source
- AstraZeneca teams with insitro in up to $1.5 billion AI partnership to target MASH and cardiomyopathiesAstraZeneca announced a partnership with AI-driven biotech insitro, committing up to $1.5 billion to discover new drug targets for metabolic dysfunction-associated steatohepatitis (MASH) and cardio…